Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Supportive care and symptom management (EONS-MASCC)

CN49 - A rapid review of patient reported outcomes for patients with renal cell cancer or hepatocellular cancer on treatment with targeted therapies

Date

22 Sep 2021

Session

Supportive care and symptom management (EONS-MASCC)

Presenters

Celia Díez de los Ríos de la Serna

Citation

Annals of Oncology (2021) 32 (suppl_5): S1275-S1281. 10.1016/annonc/annonc697

Authors

C. Díez de los Ríos de la Serna1, G. Kotronoulas2, A. Drury3, W.H. Oldenmenger4, D. Kelly5

Author affiliations

  • 1 Nursing Research, EONS, 1200 - Brussels/BE
  • 2 School Of Medicine, Dentistry & Nursing, University of Glasgow, G12 8QQ - Glasgow/GB
  • 3 School Of Nursing Midwifery And Health Systems, University College Dublin, D2 - Dublin/IE
  • 4 Medical Oncology, Erasmus MC Cancer Institute, 3015 GD - Rotterdam/NL
  • 5 N, Cardiff University - School of Healthcare Sciences, CF24 0AB - Cardiff/GB
More

Resources

Login to access the resources on OncologyPRO.

Abstract CN49

Background

Targeted therapies are an efficacious treatment option for patients with advanced renal cell carcinoma (RCC) or hepatocellular carcinoma (HCC). Targeted therapies often have low-grade toxicities that may not require intervention but may be persistent and difficult to live with, thus affecting patients’ quality of life and adherence to treatment. Patient-reported outcomes (PROs) are key indicators of health status and functioning, coming directly from the patient. Comprehensive monitoring of PROs enables implementation of person-centred care. Currently, what PROs patients with RCC or HCC consider of utmost importance remains unknown.

Methods

As part of the EONS PROMs project, a rapid literature review was carried out to identify PROs commonly assessed/reported in clinical studies of patients with advanced RCC/HCC on targeted therapies. A systematic search strategy was developed in line with PRISMA statement guidelines. We searched MEDLINE, CINAHL & PsycInfo for relevant peer-reviewed publications in the period from 2000-2021. Pre-specified selection criteria were applied to all retrieved records. Findings were integrated into a narrative synthesis.

Results

From a total of 1377 records, 81 studies met our selection criteria and were retained. Most research was on advanced RCC (n=64, 79%). 46 studies (57%) were drug trials. No qualitative research on PROs was found. Twenty-six studies (32%) employed PROs as their primary endpoint. PROs mainly featured as secondary endpoints, particularly where treatment efficacy (survival) was the focus of the study. Across studies, assessed PROs were similar for both RCC and HCC, and concerned three main areas: health-related quality of life, symptoms (cancer-related and treatment-related), and functioning. Whether selection of these PROs was patient-driven was not reported.

Conclusions

A wide range of assessed PROs were reported, however which PROs matter the most to patients with advanced RCC/HCC must be further clarified. Deficits in PROs often cause patients to seek out help. Targeting, monitoring, and responding to the ‘right’ PROs can enhance provision of person-centred care in advanced RCC/HCC and augment the clinical efficacy of targeted therapies.

Clinical trial identification

Editorial acknowledgement

Legal entity responsible for the study

European Oncology Nursing Society.

Funding

Ipsen and Eisai.

Disclosure

All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings